Disc Medicine Inc.
$ 79.72
1.77%
06 Feb - close price
- Market Cap 3,009,443,000 USD
- Current Price $ 79.72
- High / Low $ 81.28 / 78.75
- Stock P/E N/A
- Book Value 16.38
- EPS -5.37
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -0.35 %
- 52 Week High 99.50
- 52 Week Low 30.82
About
Disc Medicine Inc. (IRON) is a clinical-stage biotechnology company based in Watertown, Massachusetts, focused on pioneering therapies for patients suffering from serious hematologic disorders. With a robust pipeline that addresses critical unmet medical needs, the company employs cutting-edge drug development techniques underpinned by comprehensive scientific research. Disc Medicine's unwavering commitment to innovation positions it uniquely within the industry, as it endeavors to transform treatment approaches in hematology and significantly improve patient outcomes through its advanced therapeutics.
Analyst Target Price
$122.08
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-19 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-11 | 2023-05-15 | 2023-03-31 |
| Reported EPS | -1.77 | -1.58 | -1.02 | -0.98 | -0.8885 | -1.03 | -1.09 | -0.9 | -0.58 | -0.74 | -1.2 | -1.22 |
| Estimated EPS | -1.48 | -1.12 | -1.0738 | -1.1036 | -1.05 | -1.11 | -1 | -0.78 | -0.8 | -0.86 | -0.68 | -0.76 |
| Surprise | -0.29 | -0.46 | 0.0538 | 0.1236 | 0.1615 | 0.08 | -0.09 | -0.12 | 0.22 | 0.12 | -0.52 | -0.46 |
| Surprise Percentage | -19.5946% | -41.0714% | 5.0102% | 11.1997% | 15.381% | 7.2072% | -9% | -15.3846% | 27.5% | 13.9535% | -76.4706% | -60.5263% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.71 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IRON
2026-02-08 07:29:21
Disc Medicine, Inc. (NASDAQ:IRON) has received an average rating of "Moderate Buy" from thirteen brokerages, with a consensus one-year price target of $119.45. Despite this positive sentiment from analysts, the company's insiders have recently sold a significant number of shares, totaling approximately $24.97 million in the last quarter, reducing insider ownership to 3.64%. The company also reported an earnings per share miss for the last quarter and is forecasted to have a full-year EPS of -4.07.
2026-02-01 13:31:50
Atle Fund Management AB significantly increased its stake in Disc Medicine (NASDAQ:IRON) by 85.3% in Q3, purchasing 21,038 shares to own a total of 45,690 shares valued at about $3.02 million. This comes despite substantial insider selling, with CEO John D. Quisel selling 40,000 shares for $3.72 million and total insider sales reaching nearly $25 million in the last 90 days. The company, which is unprofitable with an expected EPS of -4.07, currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $119.45.
2026-01-29 15:01:53
Pomerantz LLP is investigating Disc Medicine, Inc. (NASDAQ: IRON) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows a Reuters report on January 15, 2026, indicating that Disc's drug development faced review delays due to safety and efficacy concerns flagged by the U.S. Food and Drug Administration. Following this news, Disc's stock price dropped by 7.84%, closing at $71.04 per share.
2026-01-28 15:59:54
Disc Medicine, Inc. (IRON) is a clinical-stage biopharmaceutical company focused on hematologic diseases, with a current market cap of $2.93 billion. Analysts have issued 12 buy ratings and an average target price of $122.08, suggesting a significant upside potential of 57.45%. The company's pipeline includes treatments for erythropoietic porphyrias, diamond-blackfan anemia, and anemia related to myelofibrosis and chronic kidney disease, positioning it for growth through innovation despite current negative earnings.
2026-01-27 19:28:02
An H.C. Wainwright & Co. report suggests that claims of a delayed FDA approval for Disc Medicine Inc.'s (IRON:NASDAQ) bitopertin are "likely noise" due to internal FDA controversies rather than issues with the drug itself. Analyst Douglas Tsao maintains confidence in the drug's approval for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), citing a 66% implied upside to the price target. The report attributes the delay allegations to Reuters shedding light on the FDA's Commissioner's National Priority Voucher (CNPV) program and increased workload, not concerns about bitopertin's efficacy or abuse potential.
2026-01-27 17:28:02
Pomerantz LLP is investigating Disc Medicine due to potential securities fraud after a drug under development faced a delay in FDA review due to safety and efficacy concerns, leading to a 7.84% stock drop. The law firm is advising affected investors about potential legal action, indicating the possibility of a class-action lawsuit. Despite this, some Wall Street analysts maintain positive outlooks and price targets for Disc Medicine's stock.
